Parent-Metabolite Pharmacokinetic Modeling of Formononetin and Its Active Metabolites in Rats after Oral Administration of Formononetin Formulations

• Published in: Pharmaceutics Vol. 15; no. 1; p. 45
• Main Authors: Kim, Ju Hee, Kang, Dong Wook, Cho, Seok-Jin, Cho, Hea-Young
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.12.2022; MDPI
• Subjects: Acids; active metabolites; Bioavailability; daidzein; dihydrodaidzein; equol; Experiments; formononetin; Ions; Laboratory animals; Metabolites; Methods; Oral administration; Pharmacokinetics; Plasma; Proteins; UPLC-MS/MS; United States > US; daidzein; equol; active metabolites; formononetin; pharmacokinetics; UPLC-MS/MS; plasma protein binding; parent-metabolite pharamcokientic modeling; dihydrodaidzein
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15010045

Formononetin is a major isoflavone contained in propolis and is reported to exhibit various pharmacological effects. However, the use of formononetin in pharmaceutical industry is limited due to its low bioavailability and solubility. There had been several efforts on formononetin formulation development, but further study is required to acquire optimal formulation. The aim of this study is to conduct pharmacokinetic (PK) evaluations after the oral administration of three formononetin formulations (20 mg/kg) in male Sprague Dawley rats. Then, a parent-metabolite PK model for formononetin was developed and evaluated for the first time. To do this, a simultaneous analysis method for formononetin and its active metabolites, daidzein, dihydrodaidzein and equol in rat plasma was developed using ultra-performance liquid chromatography tandem mass spectrometry. The separation was performed using a gradient elution of water and acetonitrile and a Kinetex C column (2.1 mm × 100 mm, 1.7 µm particle size) at a temperature of 30 ± 5 °C. The simultaneous analytical method developed in this study was validated according to international guidance and was successfully applied for the pharmacokinetic study. The time-plasma concentrations of formononetin and daidzein were well described by a two-compartment model combined with a metabolite compartment. Additionally, plasma protein binding assay was conducted in male rat plasma. The findings from the study could be used as a fundamental for the future development of formononetin as a pharmaceutical product.